8-K: Sangamo Reports Q3 2025 Results, Fabry & Neurology Progress

Sangamo Therapeutics announced its third quarter 2025 financial results and provided updates on its Fabry disease and neurology pipeline programs, including progress towards regulatory submissions.

Summary

• Consolidated net loss for Q3 2025 was $34.9 million, or $0.11 per share, a significant decline from net income of $10.7 million, or $0.04 per share, in Q3 2024.
• Revenues for Q3 2025 plummeted to $0.6 million from $49.4 million in Q3 2024, primarily due to the absence of revenue from a Genentech collaboration agreement recorded in the prior year.
• Total GAAP operating expenses decreased to $36.1 million in Q3 2025 from $38.8 million in Q3 2024, driven by lower compensation and personnel costs, partially offset by increased clinical and manufacturing expenses for the Fabry program.
• Cash and cash equivalents stood at $29.6 million as of September 30, 2025, down from $41.9 million at December 31, 2024.
• The company received a 180-day extension from Nasdaq until April 27, 2026, to regain compliance with the $1.00 minimum bid price requirement.
• Sangamo reiterated its 2025 financial guidance, expecting GAAP total operating expenses between $135 million and $155 million.
• The Fabry disease program (isaralgagene civaparvovec) showed positive detailed clinical data from the STAAR study, with the FDA reiterating agreement to use eGFR slope for accelerated approval. A Biologics License Agreement (BLA) submission is anticipated as early as Q1 2026.
• Patient enrollment has commenced for the Phase 1/2 STAND study of ST-503 for chronic neuropathic pain, with the first patient expected to be dosed in the coming months.
• Preclinical data for ST-506 in prion disease demonstrated profound survival extension in mouse models and widespread brain delivery and prion reduction in NHPs, with a Clinical Trial Application (CTA) submission expected as early as mid-2026.

Sentiment

Score: 4

Explanation: While there is positive clinical progress in the pipeline, particularly with the Fabry program moving towards BLA submission and new neurology studies commencing, the severe decline in revenue, significant net loss, and very short cash runway (into Q1 2026) present substantial financial headwinds and raise going concern risks. The Nasdaq non-compliance further adds to the negative sentiment, outweighing the clinical advancements in the short term.

Positives

• FDA reiterated its October 2024 agreement to use eGFR slope as an endpoint to support an accelerated approval pathway for isaralgagene civaparvovec in Fabry disease.
• Detailed clinical data from the registrational STAAR study for isaralgagene civaparvovec showed a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year at 52-weeks and 1.747 mL/min/1.73m2/year at 104-weeks.
• Durability of effect was demonstrated in the Fabry study, with elevated expression of alpha-galactosidase A activity maintained for up to 4.5 years for the longest treated patient.
• All 18 patients who began the Fabry study on Enzyme Replacement Therapy (ERT) had been withdrawn from ERT and remained off ERT as of the data cutoff date, with generally stable plasma lyso-Gb3 levels.
• Improvements in disease severity (FOS-MSSI score) and quality of life (SF-36, GSRS) were observed in Fabry patients.
• Isaralgagene civaparvovec demonstrated a favorable safety and tolerability profile without the requirement for preconditioning.
• Patient recruitment and enrollment are in progress for the Phase 1/2 STAND study in chronic neuropathic pain (ST-503), with the first patient expected to be dosed in the coming months.
• Updated nonclinical data for ST-503 demonstrated durability, potency, selectivity, and a favorable safety profile in nonhuman primates.
• Preclinical data for ST-506 in prion disease showed profound survival extension in disease mouse models and widespread brain delivery and prion reduction in nonhuman primates.
• Received $6 million from Pfizer upon exercise of a buyout option for a license to use certain zinc finger modified cell lines.
• Total operating expenses on a GAAP basis decreased to $36.1 million in Q3 2025 from $38.8 million in Q3 2024, primarily due to lower compensation and personnel costs.

Negatives

• Consolidated net loss for Q3 2025 was $34.9 million, a significant deterioration from net income of $10.7 million in Q3 2024.
• Revenues for Q3 2025 were $0.6 million, a substantial decrease of $48.8 million compared to $49.4 million in Q3 2024, primarily due to the absence of revenue from a Genentech collaboration agreement.
• Cash and cash equivalents decreased to $29.6 million as of September 30, 2025, from $41.9 million as of December 31, 2024.
• The company's cash and cash equivalents are only sufficient to fund planned operations into the first quarter of 2026, indicating a short cash runway and immediate need for additional funding.
• Received a 180-day extension from Nasdaq until April 27, 2026, to regain compliance with the $1.00 minimum bid price requirement, highlighting ongoing listing concerns.
• One Fabry patient who had withdrawn from ERT has since resumed ERT after the data cutoff date, despite maintaining supraphysiological levels of a-Gal A activity.

Risks

• Lack of capital resources and need for substantial additional funding to execute the operating plan and continue as a going concern.
• Risk of being unable to obtain substantial additional funding on acceptable terms or at all, or collaboration partners necessary to advance preclinical and clinical programs, particularly for the Fabry disease program.
• Potential requirement to cease operations entirely, liquidate assets, and/or seek protection under the U.S. Bankruptcy Code if funding is not secured.
• Potential for collaborators and licensees to breach or terminate their agreements.
• Risk of failing to realize expected benefits from collaboration and license agreements.
• Uncertain and costly research and development process, with preclinical results potentially not being indicative of results in future clinical trials.
• Effects of macroeconomic factors or financial challenges, including ongoing overseas conflicts, tariffs, geopolitical instability, inflation, and fluctuations in interest rates, on the global business environment and operations.
• Impacts of clinical trial delays, pauses, and holds on clinical trial timelines and commercialization of product candidates.
• Uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects observed in preliminary data may not be durable or that final data will not validate safety and efficacy.
• Risk that 104-week data from the STAAR study will not verify clinical benefit or support FDA approval, and that patients withdrawn from ERT will not remain off ERT.
• Unpredictable regulatory approval process across multiple regulatory authorities.
• Reliance on results of early clinical trials, which are not necessarily predictive of future clinical trial results.
• Potential for technological developments that could obviate technologies used by Sangamo.
• Reliance on collaborators and potential inability to secure additional collaborations.
• Inability to achieve expected future operating results.
• No assurance that commercially viable products will be developed or that milestone or royalty payments will be earned under collaboration agreements.

Future Outlook

Sangamo anticipates submitting a Biologics License Agreement (BLA) for isaralgagene civaparvovec in Fabry disease as early as the first quarter of 2026, while continuing business development discussions for a commercialization agreement. The company expects to dose the first patient in the Phase 1/2 STAND study for chronic neuropathic pain in the coming months and plans a Clinical Trial Application (CTA) submission for ST-506 in prion disease as early as mid-2026. Based on its current operating plan, cash and cash equivalents, along with recent proceeds, are projected to fund operations into the first quarter of 2026. The company reiterated its 2025 GAAP total operating expense guidance of $135 million to $155 million.

Management Comments

• "We continued to advance our clinical and pre-clinical pipeline this quarter and are excited to now be recruiting and enrolling patients in our first ever neurology clinical study following the activation of the first two clinical sites in the Phase 1/2 STAND study in chronic neuropathic pain." Sandy Macrae, Chief Executive Officer.
• "Furthermore, the announcement of detailed clinical data from our registrational STAAR study in Fabry disease, alongside our recent FDA meeting, marked important steps forward on the path to an anticipated regulatory submission for this program." Sandy Macrae, Chief Executive Officer.
• "This reflects our intention to operate a lean neurology-focused business and to advance isaralgagene civaparvovec towards a potential BLA submission, while continuing business development discussions for a Fabry commercialization agreement."

Industry Context

Sangamo Therapeutics operates in the highly competitive genomic medicine and rare disease space, focusing on gene therapies and epigenetic regulators. The progress in its Fabry disease program, particularly the FDA's agreement on eGFR slope as an accelerated approval endpoint, positions it alongside other companies developing gene therapies for rare genetic disorders. The expansion into neurology with programs for chronic neuropathic pain and prion disease leverages its proprietary zinc finger and AAV capsid technologies, aiming to address significant unmet needs in areas where current treatments are limited. The company's financial challenges, including declining revenue and a short cash runway, are common for clinical-stage biotech firms, highlighting the critical need for successful clinical development and strategic partnerships to secure commercialization and sustain operations.

Comparison to Industry Standards

• The use of eGFR slope as an endpoint for accelerated approval in Fabry disease aligns with regulatory flexibility for rare diseases, similar to how other gene therapies for conditions like Duchenne muscular dystrophy (e.g., Sarepta's Elevidys) or spinal muscular atrophy (e.g., Novartis' Zolgensma) have utilized surrogate endpoints or accelerated pathways.
• The durability of alpha-galactosidase A activity for up to 4.5 years in Fabry patients, and the ability for 18 patients to remain off ERT, suggests a potentially competitive profile against existing enzyme replacement therapies (e.g., Sanofi's Fabrazyme, Takeda's Replagal) which require lifelong infusions.
• The development of epigenetic regulators for chronic neuropathic pain (ST-503) and prion disease (ST-506) represents an innovative approach within neurology, where many competitors focus on small molecules or biologics. The STAC-BBB capsid for brain delivery is a key differentiator, aiming to overcome blood-brain barrier challenges that limit many CNS therapies.
• The Nasdaq minimum bid price non-compliance is a common issue for smaller biotech companies with volatile stock prices, often seen with peers facing similar funding and development stage challenges.

Stakeholder Impact

• Shareholders: Significant dilution risk due to potential capital raises, risk of delisting from Nasdaq, and potential for substantial share price volatility given the financial losses and short cash runway. Positive clinical data could provide upside, but financial stability is a major concern.
• Employees: Potential for workforce reductions or operational restructuring if additional funding is not secured, given the stated intention to operate a 'lean neurology-focused business.'
• Patients (Fabry Disease): Potential for a new, durable, one-time treatment option (isaralgagene civaparvovec) if regulatory approval is achieved, offering a significant improvement over current lifelong ERT.
• Patients (Chronic Neuropathic Pain, Prion Disease): Hope for novel treatment options in areas of high unmet medical need as clinical trials advance.
• Creditors/Suppliers: Increased risk due to the short cash runway and going concern warning, potentially impacting payment terms or future engagements.

Next Steps

• Dose the first patient in the Phase 1/2 STAND study for chronic neuropathic pain in the coming months.
• Prepare for an anticipated Biologics License Agreement (BLA) submission for isaralgagene civaparvovec in Fabry disease as early as Q1 2026.
• Continue business development discussions for a Fabry commercialization agreement.
• Submit a Clinical Trial Application (CTA) for ST-506 in prion disease as early as mid-2026.
• Regain compliance with Nasdaq's $1.00 minimum bid price requirement by April 27, 2026.
• Secure substantial additional funding to continue operations beyond Q1 2026.

Key Dates

Recommendation

Despite promising clinical progress in the Fabry disease program and advancements in the neurology pipeline, the severe financial deterioration, including a substantial net loss and a drastic decline in revenue, coupled with a critically short cash runway into Q1 2026, presents an immediate and significant risk to the company's viability. The Nasdaq non-compliance further underscores the precarious financial position. The explicit 'going concern' warning and the urgent need for substantial additional funding, with no guarantee of success, make the stock a high-risk investment. While the long-term potential of the pipeline exists, the near-term financial instability and the high probability of significant dilution or even cessation of operations warrant a 'sell' recommendation for investors seeking to mitigate risk.

Keywords

Sangamo Therapeutics, SGMO, Fabry disease, gene therapy, isaralgagene civaparvovec, ST-920, eGFR slope, accelerated approval, FDA, neuropathic pain, ST-503, prion disease, ST-506, genomic medicine, zinc finger, Q3 2025 earnings, financial results, Nasdaq compliance, cash runway, biotechnology, clinical trials, rare disease